Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Osteoporosis drug 'could prevent breast cancer spread'

  • Comment

An osteoporosis drug could be used to prevent the spread of breast cancer to other parts of the body, a study has suggested.

A report published in the online version of the Lancet Oncology found that Zoledronic acid, when used with chemotherapy, significantly reduced the number of detectable tumours after three months of treatment.

It is thought the drug alters the body’s micro-environment, making it more hostile to cancer cells and thus reducing the risk of metastatic disease.

Around 25% of breast cancers spread to the bone, with marrow often acting as a sanctuary for disseminated tumour cells (DTCs) released from the primary cancer.

Earlier research has shown that chemotherapy may promote tumour growth in women with breast cancer by increasing the rate of bone turnover - a process that releases growth hormones.

The report said: “Zoledronic acid has antimetastatic properties within the bone marrow and systemically.

“Chemotherapy leads to increased bone turnover and the release of growth factors, providing a favourable environment for DTCs, and that this effect is abrogated by treatment with bisphosphonates.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.